CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pivotal Trial of Lasmiditan in Migraine First Patient Randomized in SPARTAN StudyTrial Being Conducted Under Special Protocol Assessment Agreement with FDA CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals,...

CoLucid Pharmaceuticals and IMS Health Publish White Paper to Address Migraine Market Misperceptions CAMBRIDGE, MA, Jan. 05, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...